Please select the option that best describes you:
Topics:
Hematologic Malignancies • Pediatric Hematology/Oncology • Bone Marrow Transplant • Internal Medicine • Hematology
What is your escalation strategy for chronic GvHD?
How does belumosudil now fit in your approach to steroid refractory chronic graft-versus-host disease?
Answer from: at Academic Institution
There are now several available options for steroid resistant cGVHD. The old standbys - ECP and rituxan are useful in about 30% of patients. Ibrutinib was the first new drug to get FDA approval. Unfortunately, I don't think the real-world experience is anywhere near as good as the trial (Chin et al....
Sign in or Register to read more